1 Result: Pulmonx
Pulmonx Beats Estimates; Strategic Move Boosts TransCode Therapeutics
October 30th, 2023
Pulmonx Corporation (Nasdaq: LUNG) reported a narrower loss than expected in the third quarter of 2023, posting a loss of $(0.39) per share, surpassing the consensus estimate loss of $(0.43) per share. The company's quarterly sales stood at $17.67 mi. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
What Wall Street Expects From Keysight, Mercury Systems, and Amer Sports: Earnings Preview
August 15th, 2026FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies
August 13th, 2026August 12th, 2026
Member Login